ADL Amdl,

TUSTIN, Calif., July 26 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that it anticipates receiving approximately $261,600 from the conversion of expiring options held by various Company directors. These selected directors hold approximately 109,000 common stock options at a conversion price of $2.40 per share. "We believe our Directors are reinforcing their strong faith in the future of the Company," said Gary Dreher, CEO. "This welcome additional paid-in capital will be used for general working capital purposes and to further Jade Pharmaceutical's current marketing efforts." About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards. About AMDL: More information about AMDL and its products is available at http://www.amdl.com/ . Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul Knopick, AMDL Investor Relations, Direct Line, +1-949- 707-5365, or Voice Mail, +1-714-505-4460 Web site: http://www.amdl.com/

Copyright